Kaposi sarcoma–associated herpesvirus: immunobiology, oncogenesis, and therapy
Dirk P. Dittmer, Blossom Damania
Dirk P. Dittmer, Blossom Damania
Published September 1, 2016
Citation Information: J Clin Invest. 2016;126(9):3165-3175. https://doi.org/10.1172/JCI84418.
View: Text | PDF
Review

Kaposi sarcoma–associated herpesvirus: immunobiology, oncogenesis, and therapy

Abstract

Kaposi sarcoma–associated herpesvirus (KSHV), also known as human herpesvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. This human gammaherpesvirus was discovered in 1994 by Drs. Yuan Chang and Patrick Moore. Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus.

Authors

Dirk P. Dittmer, Blossom Damania

×

Figure 3

KSHV vGPCR, K1, K15, and vIL-6 proteins impact the PI3K/AKT/mTOR signaling pathway.

Options: View larger image (or click on image) Download as PowerPoint
KSHV vGPCR, K1, K15, and vIL-6 proteins impact the PI3K/AKT/mTOR signali...
Multiple KSHV viral proteins activate the PI3K/AKT/mTOR signaling pathway at different nodes in this pathway. Activation of this pathway ultimately results in cell survival and cell proliferation.